Differences in the Volatilomic Urinary Biosignature of Prostate Cancer Patients as a Feasibility Study for the Detection of Potential Biomarkers
Sign Up to like & getrecommendations! Published in 2023 at "Current Oncology"
DOI: 10.3390/curroncol30050370
Abstract: Prostate cancer (PCa) continues to be the second most common malignant tumour and the main cause of oncological death in men. Investigating endogenous volatile organic metabolites (VOMs) produced by various metabolic pathways is emerging as… read more here.
Keywords: prostate cancer; differences volatilomic; pca; biosignature ... See more keywords